Background: The one previous prospective study of vitamin D status and risk of urinary
Introduction
Laboratory studies provide evidence that vitamin D promotes cell differentiation, and decreases cell proliferation, invasion, angiogenesis, and metastasis [1, 2] . Thus, it has been hypothesized that vitamin D may protect against cancer at multiple sites.
Most epidemiologic evidence supports a protective association with colorectal cancer, but evidence concerning other cancers is inconsistent [1, 3] . For urinary bladder cancer, only one study has examined vitamin D status, as measured by serum 25-hydroxyvitamin D (25(OH)D) concentration, which showed that male smokers with low 25(OH)D had a nearly two-fold increased risk of bladder cancer compared to men with higher levels [4] . 
Methods
The PLCO Study has been described in detail previously [5] . Bladder cancer cases (n=369) with pre-diagnosis serum available occurred during 13 years of follow-up.
Controls were sampled with replacement from PLCO Study participants who were alive and cancer free at the time the case was diagnosed and were matched 1:1 to cases on age (+/-5 years), race, sex, and date of blood collection (+/-30 days). (QC) duplicates from four PLCO study participants. The range of inter-and intra-batch CVs across the four sets of duplicates were: 25(OH)D: 3.7-6.9% and 4.8-8.1%, respectively; DBP: 3.2-11.1% and 9.5-12.6%, respectively.
Conditional logistic regression was used to estimate odds ratios and 95% confidence intervals for bladder cancer by pre-diagnosis concentrations of 25(OH)D categorized as previously described [6] . We also examined quartiles of DBP as well as the molar ratio of 25(OH)D:DBP (an estimate of free circulating 25(OH)D) and risk of bladder cancer.
Models were conditioned on the matching factors. Multivariable models were further adjusted for smoking status (never, current, former), pack-years of smoking (continuous), dairy consumption (continuous), and use of aspirin or ibuprofen (yes/no).
Subgroup analyses were conducted stratifying by age (<64, ≥64 years), sex (male, female), race (white, non-white), smoking (never or former, current), season (sunnier: June-October, darker: November-May), study center (low UVB exposure latitude, moderate or high UVB exposure latitude) [7] , and DBP (<median, ≥ median).
Interaction was assessed using the likelihood ratio test.
Results
Characteristics of cases and controls are shown in Table 1 . We did not observe a strong association between serum 25(OH)D and bladder cancer ( Table 2 ). An inverted U-shaped association was suggested, particularly when 25(OH)D was categorized as season-specific quartiles. This was attenuated with multivariable adjustment and was not statistically significant. Adjustment for serum DBP did not alter the findings, nor was 
Discussion
We found no evidence of an association between vitamin D and risk of bladder cancer. Neither adjustment for nor stratification by DBP changed the association with vitamin D. These results differ from those of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) study of male smokers which found a protective association between vitamin D and bladder cancer risk [4] . This difference may be explained by the inclusion of women and non-smokers in the current analysis, as restricting the analysis to male smokers showed a modest inverse association. Although our study was sufficiently powered to detect an OR of 1.7 comparing the lowest to highest vitamin D quartile (i.e., higher risk similar in magnitude to that previously observed [4] ), we did not have power to detect a weaker association, particularly in subgroups. Future studies should plan to examine differences in the association by gender and smoking status. 
